Damora Therapeutics Inc. – Material Contracts Watch

from 8-K 11 pages Position. as General Counsel and Corporate Secretary, You Will Continue to Report to the Chief Executive Officer of the Company, and You Shall Have All Duties, Authorities, and Responsibilities Customarily Associated With the General Counsel and Corporate Secretary Position. This Is a Full-Time Employment Position. It Is Understood and Agreed That You Shall Continue Not to Engage in Any Other Employment, Consulting or Other Business Activities (Whether Full-Time or Part-Time), Except as Expressly Authorized in Writing by the Company. Notwithstanding the Foregoing, You May Engage in Religious, Charitable and Other Community Activities So Long as Such Activities Do Not Unreasonably Interfere or Conflict With Your Obligations to the Company. 2. Compensation

from 8-K 13 pages Positions. as CEO, You Will Report to the Board, and You Shall Have All Duties, Authorities, and Responsibilities Customarily Associated With the CEO Position. This Is a Full-Time Employment Position. It Is Understood and Agreed That You Will Not Engage in Any Other Employment, Consulting or Other Business Activities (Whether Full-Time or Part-Time), Except as Set Forth on Appendix a Hereto or as Expressly Authorized in Writing by the Board. Notwithstanding the Foregoing, You May Engage in Religious, Charitable and Other Community Activities, in Each Case, So Long as Such Activities Do Not Unreasonably Interfere or Conflict With Your Obligations to the Company. 2. Compensation

from 10-K 2 pages November 10, 2025 Lori Firmani Dear Lori: As You May Know, Galecto, Inc. (The “Company”) Recently Entered Into That Certain Agreement and Plan of Merger, Effective November 10, 2025, Pursuant to Which the Company Acquired Damora Therapeutics, Inc., a Delaware Corporation, in an All-Stock Transaction (The “Transaction”)

from 10-K 4 pages Congratulations! Galecto, Inc. ("Galecto" or the "Company") Is Very Pleased to Offer You Employment With the Following Initial Terms: Position

from 10-K 2 pages November 10, 2025 Garrett Winslow

from 10-K 12 pages Positions. as Cmo, You Will Report to the Chief Executive Officer of the Company (“CEO”) and You Shall Have All Duties, Authorities, and Responsibilities Customarily Associated With the Cmo Position. This Is a Full-Time Employment Position. It Is Understood and Agreed That You Will Not Engage in Any Other Employment, Consulting or Other Business Activities (Whether Full-Time or Part-Time), Except as Expressly Authorized in Writing by the Company. Notwithstanding the Foregoing, You May (A) Serve on Boards of Directors (For Profit or Non-Profit) and Scientific Advisory Boards of Other Companies or Organizations With the Approval of the CEO, Which Shall Not Be Unreasonably Withheld, (B) Engage in Other Business Activities With Advanced Noticed to the CEO and (C) Engage in Religious, Charitable and Other Community Activities, in Each Case, So Long as Such Activities Do Not Unreasonably Interfere or Conflict With Your Obligations to the Company (“Outside Activities”). You May Keep Any Compensation Received as a Result of Your Outside Activities, and the Company Shall Not Have Any Right to Such Compensation. the Company Acknowledges and Hereby Expressly Approves of Your Service and/or Continued Service on the Scientific Advisory Boards of Tasca Therapeutics, Alessa Therapeutics and Cellery. 2. Compensation

from 10-K 8 pages Galecto Biotech Aps Cvr No. 34878366 Ole Maaløes Vej 3 2200 Copenhagen (The "Company") and Galecto Biotech Ab Ole Måløes Vej 3 2200 Copenhagen and Galecto, Inc. 75 State Street, Suite 100 Boston, Ma 02109 and Hans Thalsgård Schambye Rigensgade 9b, St. 1316 Copenhagen (The "CEO") (Each a "Party" and Collectively Referred to as the "Parties") Have Today Entered Into This Separation Agreement (The "Separation Agreement"). 1. Termination of Employment 1.1 by Service Agreement of 23 April 2013 (The "Service Agreement"), the CEO Was Employed With the Company and Galecto Biotech Ab on 1 February 2013. the CEO Was a Member of the Board of Directors of the Company, Galecto Biotech Ab and Galecto, Inc. (Collectively, the “Company Group”). 1.2 the Parties Have Mutually Agreed That the CEO Will No Longer Serve in His Position as CEO Effective as of 10 February 2026 at 12:01 Am Et and Will Terminate Employment as of the Date the Parties Have Signed the Separation Agreement (The "Effective Date of Termination"). 1.3 Consequently, the Parties Have Entered Into the Separation Agreement Concerning Their Rights and Obligations in Relation to the Cessation of the Employment. 2. De-Registration; Resignation From Directorships 2.1 the Company Will as Soon as Practically Possible Provide for the De-Registration of the CEO as CEO and a Member of the Board of Directors of the Company and Galecto Biotech Ab With the Danish Business Authority and Swedish Commerce Companies Agency (Erhvervsstyrelsen And

from 10-K 3 pages Galecto Biotech Aps Cvr No. 34878366 Ole Maaløes Vej 3 2200 København N (The "Company") and Hans Thalsgård Schambye Rigensgade 9b, St. 1316 København K (The "CEO") (Each a "Party" and Collectively Referred to as the "Parties") Have Today Entered Into This Retention Bonus Agreement (The "Retention Bonus Agreement") Relating to the Service Agreement Between the Parties, Dated 23 April 2013 (The “Service Agreement”). 1. Background 1.1 Galecto, Inc., Parent Company of the Company (“Parent”), Recently Entered Into That Certain Agreement and Plan of Merger, Effective November 10, 2025, Pursuant to Which Parent Acquired Damora Therapeutics, Inc., a Delaware Corporation, in an All-Stock Transaction (The “Transaction”). 1.2 the Parties Agree That the CEO Will Be Entitled to Receive a Retention Bonus on the Terms and Conditions Outlined in This Retention Bonus Agreement. 2. Bonus 2.1 Subject to Clause 2.2 Below, the CEO Will Be Entitled to Receive a Retention Bonus (The “Retention Bonus”) Equal to Dkk 2,173,800 if He Remains Employed by the Company or an Affiliate of the Company Through the Earlier Of: (I) April 30, 2026; or (II) His Termination by the Company Without Cause (As Defined in Galecto Inc.’s Executive Separation Benefits Plan (The “Executive Separation Benefits Plan”)) (The Earlier of (I) or (II) Is the “Retention Date”). Payment of the Retention Bonus Will Be Made Within 30 Days of the Retention Date. 2.2 for the Avoidance of Doubt, if the CEO Is Not Employed With the Company at the Retention Date, He Will Not Be Entitled to Receive the Retention Bonus. 3. Other Terms and Conditions 3.1

from 10-K 42 pages The Purpose of This 2025 Equity Incentive Plan (The “Plan”) of Damora Therapeutics, Inc., a Delaware Corporation (The “Company”), Is to Advance the Interests of the Company’s Stockholders by Enhancing the Company’s Ability to Attract, Retain and Motivate Persons Who Are Expected to Make Important Contributions to the Company and by Providing Such Persons With Equity Ownership Opportunities and Performance-Based Incentives That Are Intended to Better Align the Interests of Such Persons With Those of the Company’s Stockholders. Except Where the Context Otherwise Requires, the Term “Company” Shall Include Any of the Company’s Present or Future Parent or Subsidiary Corporations as Defined in Sections 424(e) or (F) of the Internal Revenue Code of 1986, as Amended, and Any Regulations Promulgated Thereunder (The “Code”) and Any Other Business Venture (Including, Without Limitation, Joint Venture or Limited Liability Company) in Which the Company Has a Controlling Interest, as Determined by the Board of Directors of the Company (The “Board”). 2. Eligibility. All of the Company’s Employees, Officers, Directors, Consultants and Advisors Are Eligible to Be Granted Options, Restricted Stock, Restricted Stock Units, and Other Stock-Based Awards (Each, an “Award”) Under the Plan. Each Person Who Receives an Award Under the Plan Is Deemed a “Participant”. 3. Administration and Delegation

from S-3ASR 34 pages Recitals Article 1 Defined Terms

from 8-K 12 pages Positions. as COO, You Will Report to the Chief Executive Officer of the Company (“CEO”) and You Shall Have All Duties, Authorities, and Responsibilities Customarily Associated With the COO Position. This Is a Full-Time Employment Position. It Is Understood and Agreed That You Will Not Engage in Any Other Employment, Consulting or Other Business Activities (Whether Full-Time or Part-Time), Except as Expressly Authorized in Writing by the Company. Notwithstanding the Foregoing, You May (A) Serve on Boards of Directors and Scientific Advisory Boards of Other Companies or Organizations (Profit or Non-Profit) Subject to the Approval of the CEO, Which Shall Not Be Unreasonably Withheld, (B) Engage in Other Business Activities With Advanced Noticed to the CEO and (C) Engage in Religious, Charitable and Other Community Activities, in Each Case, So Long as Such Activities Do Not Unreasonably Interfere or Conflict With Your Obligations to the Company. 2. Compensation

from S-3 34 pages Recitals Article 1 Defined Terms

from 8-K 22 pages Registration Rights Agreement

from 8-K 38 pages Securities Purchase Agreement

from 10-K 2 pages English Summary of a Lease Agreement Dated November 11, 2024 (The “Lease”) by and Between Galecto Biotech Aps (“Galecto”) and Symbion a/S (The “Landlord”) • Leased Property: The Lease Is for the Purpose of Office Space, With Its Address: Ole Maaloes Vej 3, Dk-2200 Copenhagen N, Denmark. • Term: The Term Started December 1, 2024 and Will End on November 30, 2029. • Deposit: Galecto Must Provide a Deposit Equivalent to Three Months’ Rent (Dkk 25,160), Excluding Vat for Securing Its Obligations. • Permitted Use: The Permitted Use Is for Office Space. • Sublease/Termination: Galecto Is Not Permitted to Sublease the Property, but May Terminate the Lease at the Beginning of a Month With Three Months’ Advance Notice. • Rent: Dkk 129,595 Annually, Including Vat, Based on the Rental Area of Approximately 350 Square Feet

from 10-K 36 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Bridge Medicines License Agreement

from 10-K 4 pages October 7, 2024 Garrett Winslow [Address] Re: Retention Compensation Dear Garrett

from 10-K 4 pages Galecto Biotech Aps Cvr No. 34878366 Ole Maaløes Vej 3 2200 København N (The "Company") and Hans Thalsgård Schambye [Address] (The "CEO") (Each a "Party" and Collectively Referred to as the "Parties") Have Today Entered Into This Retention Agreement (The "Retention Agreement") Relating to the Service Agreement Between the Parties, Dated 23 April 2013 (The “Service Agreement”). 1. Background 1.1 the Parties Agree That the CEO Will Be Entitled to Receive a Retention Bonus on the Terms and Conditions Outlined in This Retention Agreement. 2. Bonus 2.1

from 10-K 3 pages Galecto, Inc. Non-Employee Director Compensation Policy

from 8-K 12 pages Galecto, Inc. Support Agreement